IL225852A0 - Resjalin is enriched in deuterium - Google Patents

Resjalin is enriched in deuterium

Info

Publication number
IL225852A0
IL225852A0 IL225852A IL22585213A IL225852A0 IL 225852 A0 IL225852 A0 IL 225852A0 IL 225852 A IL225852 A IL 225852A IL 22585213 A IL22585213 A IL 22585213A IL 225852 A0 IL225852 A0 IL 225852A0
Authority
IL
Israel
Prior art keywords
deuterium enriched
rasagiline
enriched rasagiline
deuterium
enriched
Prior art date
Application number
IL225852A
Other languages
English (en)
Hebrew (he)
Original Assignee
Teva Pharma
Bahar Eliezer
Piryatinsky Victor
Frenkel Anton
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45973513&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL225852(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teva Pharma, Bahar Eliezer, Piryatinsky Victor, Frenkel Anton filed Critical Teva Pharma
Publication of IL225852A0 publication Critical patent/IL225852A0/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00Compounds containing amino groups bound to a carbon skeleton
    • C07C211/43Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C07C211/57Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings being part of condensed ring systems of the carbon skeleton
    • C07C211/60Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings being part of condensed ring systems of the carbon skeleton containing a ring other than a six-membered aromatic ring forming part of at least one of the condensed ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00Compounds containing amino groups bound to a carbon skeleton
    • C07C211/33Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C211/39Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton
    • C07C211/41Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems
    • C07C211/42Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems with six-membered aromatic rings being part of the condensed ring systems
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01NPRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N33/00Biocides, pest repellants or attractants, or plant growth regulators containing organic nitrogen compounds
    • A01N33/02Amines; Quaternary ammonium compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/001Acyclic or carbocyclic compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C209/00Preparation of compounds containing amino groups bound to a carbon skeleton
    • C07C209/68Preparation of compounds containing amino groups bound to a carbon skeleton from amines, by reactions not involving amino groups, e.g. reduction of unsaturated amines, aromatisation, or substitution of the carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05Isotopically modified compounds, e.g. labelled
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00Systems containing two condensed rings
    • C07C2602/02Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Plant Pathology (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Dentistry (AREA)
  • Pest Control & Pesticides (AREA)
  • Agronomy & Crop Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
IL225852A 2010-10-26 2013-04-21 Resjalin is enriched in deuterium IL225852A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40674010P 2010-10-26 2010-10-26
PCT/US2011/057698 WO2012058219A2 (en) 2010-10-26 2011-10-25 Deuterium enriched rasagiline

Publications (1)

Publication Number Publication Date
IL225852A0 true IL225852A0 (en) 2013-06-27

Family

ID=45973513

Family Applications (1)

Application Number Title Priority Date Filing Date
IL225852A IL225852A0 (en) 2010-10-26 2013-04-21 Resjalin is enriched in deuterium

Country Status (17)

Country Link
US (2) US20120101168A1 (enExample)
EP (1) EP2632254A4 (enExample)
JP (1) JP2014503480A (enExample)
KR (1) KR20140023872A (enExample)
CN (1) CN103188933A (enExample)
AU (1) AU2011320611A1 (enExample)
BR (1) BR112013010308A2 (enExample)
CA (1) CA2816104A1 (enExample)
CL (1) CL2013001101A1 (enExample)
EA (1) EA201390613A1 (enExample)
IL (1) IL225852A0 (enExample)
MX (1) MX2013004598A (enExample)
NZ (1) NZ610526A (enExample)
PH (1) PH12013500821A1 (enExample)
SG (2) SG10201508771TA (enExample)
WO (1) WO2012058219A2 (enExample)
ZA (1) ZA201303505B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1991214B1 (en) * 2006-02-21 2015-08-05 Teva Pharmaceutical Industries, Ltd. Use of rasagiline for the treatment of multiple system atrophy
EP2007369A4 (en) 2006-04-03 2009-07-01 Teva Pharma USE OF RASAGILINE FOR THE TREATMENT OF LEG SYNDROME WITHOUT REST
EA016820B1 (ru) * 2006-12-14 2012-07-30 Тева Фармасьютикал Индастриз, Лтд. Кристаллическое твердое основание разагилина
EP1987816A1 (de) * 2007-04-30 2008-11-05 Ratiopharm GmbH Adsorbate eines Rasagilinsalzes mit einem wasserlöslichen Hilfsstoff
NZ586025A (en) * 2008-01-11 2012-08-31 Teva Pharma Rasagiline mesylate tablet coated with a composisiton comprising methacrylic acid - ethyl acrylate copolymer and triethyl citrate
ES2389353T3 (es) * 2008-06-10 2012-10-25 Teva Pharmaceutical Industries Ltd. Cápsulas de gelatina blanda de rasagilina
RS53504B1 (sr) 2009-07-09 2015-02-27 Ratiopharm Gmbh Soli razagilina i njihovi farmaceutski preparati
US20110130466A1 (en) * 2009-10-09 2011-06-02 Stefan Lorenzl Use of rasagiline for the treatment of progressive supranuclear palsy
EP2939669A1 (en) * 2009-12-22 2015-11-04 Teva Pharmaceutical Industries, Ltd. 3-keto-n-propargyl-1-aminoindan
AU2011282716A1 (en) 2010-07-27 2013-03-14 Teva Pharmaceutical Industries Ltd. Dispersions of rasagiline citrate
AU2011282720B2 (en) 2010-07-27 2016-12-22 Teva Pharmaceutical Industries Ltd. Use of rasagiline for the treatment of olfactory dysfunction
KR20140090996A (ko) 2011-10-10 2014-07-18 테바 파마슈티컬 인더스트리즈 리미티드 R(+)-n-폼일-프로파길-아미노인단
AU2012323351A1 (en) 2011-10-10 2014-05-22 Teva Pharmaceutical Industries Ltd. R(+)-N-methyl-propargyl-aminoindan
JP2015529196A (ja) 2012-08-17 2015-10-05 テバ ファーマシューティカル インダストリーズ リミティド ラサギリンの非経口製剤
CN113348018B (zh) * 2018-12-06 2025-04-01 内在生物技术有限公司 乙酰基-亮氨酸的氘代类似物
CN111323524B (zh) * 2020-04-08 2022-04-15 重庆华森制药股份有限公司 一种炔丙胺及其杂质的检测方法
CN115947675B (zh) * 2022-12-21 2024-05-31 博济医药科技股份有限公司 一种雷沙吉兰中间体及其制备方法和应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744500A (en) 1990-01-03 1998-04-28 Teva Pharmaceutical Industries, Ltd. Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
IL92952A (en) 1990-01-03 1994-06-24 Teva Pharma R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them
EP1778196A4 (en) * 2004-07-26 2008-12-17 Teva Pharma PHARMACEUTICAL DOSAGES CONTAINING RASAGILINE
CN101098685A (zh) * 2004-11-24 2008-01-02 特瓦制药工业有限公司 雷沙吉兰经口崩解组合物
CA2600008A1 (en) * 2005-02-22 2006-11-16 Teva Pharmaceutical Industries Ltd. Improved process for the synthesis of enantiomeric indanylamine derivatives
AU2006310100B2 (en) * 2005-11-06 2012-12-06 Brain Watch Ltd. Magnetic resonance imaging and spectroscopy means and methods thereof
CN102203053B (zh) * 2008-06-02 2015-11-25 基因里克斯(英国)有限公司 用于制备胺的改进方法
JP2011522892A (ja) * 2008-06-13 2011-08-04 テバ ファーマシューティカル インダストリーズ リミティド パーキンソン病緩和のためのラサギリン
US20100172916A1 (en) * 2008-11-10 2010-07-08 Auspex Pharmaceuticals, Inc. Substituted hydroxyphenylamine compounds
US8080584B2 (en) * 2009-01-23 2011-12-20 Teva Pharmaceuticals Industries, Ltd. Delayed release rasagiline citrate formulation
US20100286124A1 (en) * 2009-04-10 2010-11-11 Auspex Pharmaceuticals, Inc. Prop-2-yn-1-amine inhibitors of monoamine oxidase type b
EP2473199A1 (en) * 2009-08-31 2012-07-11 Brain Watch Ltd. Isotopically labeled neurochemical agents and uses thereof for diagnosing conditions and disorders

Also Published As

Publication number Publication date
US20140364506A1 (en) 2014-12-11
PH12013500821A1 (en) 2019-07-03
WO2012058219A3 (en) 2012-07-26
SG10201508771TA (en) 2015-11-27
CL2013001101A1 (es) 2013-09-06
EP2632254A2 (en) 2013-09-04
AU2011320611A1 (en) 2013-06-13
NZ610526A (en) 2015-10-30
MX2013004598A (es) 2013-07-17
CA2816104A1 (en) 2012-05-03
SG189454A1 (en) 2013-05-31
EA201390613A1 (ru) 2013-11-29
CN103188933A (zh) 2013-07-03
EP2632254A4 (en) 2015-08-05
WO2012058219A2 (en) 2012-05-03
ZA201303505B (en) 2015-08-26
KR20140023872A (ko) 2014-02-27
BR112013010308A2 (pt) 2016-07-05
JP2014503480A (ja) 2014-02-13
US20120101168A1 (en) 2012-04-26

Similar Documents

Publication Publication Date Title
ZA201303505B (en) Deuterium enriched rasagiline
AU333439S (en) Wristband
IL225514A0 (en) jewel
IL222763A0 (en) Isotope preparation method
IL231720A0 (en) rasagiline citramide
GB2485334B (en) Structure
GB2505906B (en) Multicoordination scheduling
EP2553598A4 (en) ACCOMPANYING EXPERIENCE
IL230287A0 (en) Metabolites of trans-clomiphene and their uses
SG10201503142SA (en) Hydroalkylation processes
GB201222891D0 (en) Exercise system
GB201121846D0 (en) Sign
EP2591985A4 (en) PANEL ASSEMBLY STRUCTURE
GB2482320B (en) Headgear-mountable respirator
GB201104927D0 (en) Breathing devices
GB201019676D0 (en) Sign
GB2524676B (en) Headgear-mountable respirator
TWM388240U (en) Earring structure
HK1188908A (en) Deuterium enriched rasagiline
AU4772P (en) U2 Neotyphodium uncinatum
GB2486217B (en) Posters
GB201120484D0 (en) Isotopic labelling or higher organisms
AU333206S (en) Respirator
GB201106037D0 (en) Enriched stimulation system
GB201014722D0 (en) Een